Figitumumab (CP-751,871) for cancer therapy

Bibliography

• LeRoith D, Toberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37
   PubMed Web of Science ®Google Scholar
• Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94:465-8
   PubMed Web of Science ®Google Scholar
• Yuen JS, Macaulay VM. Targeting the Type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008;12:589-603
   PubMed Web of Science ®Google Scholar
• Himpe E, Kooijman R. Insulin-like growth factor-I receptor signal transduction and the janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. Biofactors 2009;35:76-81
   Google Scholar
• Hernández-Sánchez C, Mansilla A, de Pablo F, Evolution of the insulin receptor family and receptor isoform expression in vertebrates. Mol Biol Evol 2008;25:1043-53
   PubMed Web of Science ®Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18
   PubMed Web of Science ®Google Scholar
• Liu JP, Baker J, Perkins AS, Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and Type 1 IGF receptor (Igf1r). Cell 1993;75:59-72
   PubMed Web of Science ®Google Scholar
• Abuzzahab MJ, Schneider A, Goddard A, IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003;349:2211-22
   PubMed Web of Science ®Google Scholar
• Liu JP, Baker J, Perkins AS, Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I) and Type 1 IGF receptor (Igf1r). Cell 1993;75:59-72
   PubMed Web of Science ®Google Scholar
• Laustsen PG, Russell SJ, Cui L, Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol 2007;27:1649-64
   PubMed Web of Science ®Google Scholar
• Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005;26:916-43
   PubMed Web of Science ®Google Scholar
• Frystyk J, Ivarsen P, Skjaerbaek C, Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999;56:2076-84
   PubMed Web of Science ®Google Scholar
• Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor 1 on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 1989;86:2868-72
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, Criqui MH, The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004;89:114-20
   PubMed Web of Science ®Google Scholar
• Ezzat VA, Duncan ER, Wheatcroft SB, The role of IGF-I and its binding proteins in the development of Type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 2008;10:198-211
   PubMed Web of Science ®Google Scholar
• Janssen JA, Lamberts SW. The role of IGF-I in the development of cardiovascular disease in Type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002;146:467-77
   PubMed Web of Science ®Google Scholar
• Holzenberger M, Dupont J, Ducos B, IGF-I receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003;421:182-7
   PubMed Web of Science ®Google Scholar
• Holzenberger M. The GH/IGF-I axis and longevity. Eur J Endocrinol 2004;151(Suppl 1):S23-7
   PubMed Web of Science ®Google Scholar
• Suh Y, Atzmon G, Cho MO, Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA 2008;105:3438-42
   PubMed Web of Science ®Google Scholar
• Pinkston-Gosse J, Kenyon C. DAF-16/FOXO targets genes that regulate tumor growth in Caenorhabditis elegans. Nat Genet 2007;39:1403-9
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16(1):3-34
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74
   PubMed Web of Science ®Google Scholar
• O'Connor R. Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res 2003;35:771-7
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, Rapamycin induces feedback activation of Akt signaling through an IGF-IR-dependent mechanism. Oncogene 2007;26:1932-40
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12
   PubMed Web of Science ®Google Scholar
• Yuen JS, Macaulay VM. Targeting the Type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008;12:589-603
   PubMed Web of Science ®Google Scholar
• Samani AA, Yakar S, LeRoith D, The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47
   PubMed Web of Science ®Google Scholar
• Baserga R, Peruzzi F, Reiss K. The IGF-I receptor in cancer biology. Int J Cancer 2003;107:873-7
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28
   PubMed Web of Science ®Google Scholar
• Chitnis MM, Yuen JS, Protheroe AS, The Type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14:6364-70
   PubMed Web of Science ®Google Scholar
• Hartog H, Wesseling J, Boezen HM, The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007;43:1895-904
   PubMed Web of Science ®Google Scholar
• Mendez MJ, Green LL, Corvalan JRF, Functional transplant of megabase human immunoglobin loci recapitulates human antibody response in mice. Nat Genet 1997;15:146-56
   PubMed Web of Science ®Google Scholar
• Cohen BD, Baker DA, Soderstrom C, Combination therapy enhances the inhibition of tumor growth with the fully human anti–Type 1 insulin–like growth factor receptor monoclonal antibody figitumumab. Clin Cancer Res 2005;11:2063-73
   PubMed Web of Science ®Google Scholar
• O'Mahony D, Bishop MR. Monoclonal antibody therapy. Front Biosci 2006;11:1620-35
   PubMed Web of Science ®Google Scholar
• Iwasa T, Okamoto I, Suzuki M, Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 2009;15:5117-25
   PubMed Web of Science ®Google Scholar
• Kurmasheva RT, Dudkin L, Billups C, The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Alsina M, Fonseca R, Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor Type 1 Receptor monoclonal antibody figitumumab in patients with multiple myeloma. J Clin Oncol. 2008;26(19):3196-203
   PubMed Web of Science ®Google Scholar
• Haluska P, Shaw HM, Batzel GN, Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody figitumumab in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40
   PubMed Web of Science ®Google Scholar
• Haluska P, Worden F, Olmos D, Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010;65:765-73
   PubMed Web of Science ®Google Scholar
• Olmos D, Postel-Vinay S, Molife LR, Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a Phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35
   PubMed Web of Science ®Google Scholar
• Karp DD, Pollak MN, Cohen RB, Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor Type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009;4:1397-403
   PubMed Web of Science ®Google Scholar
• Attard G, Fong PC, Molife R, Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of figitumumab (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-IR), with docetaxel (D) in patients (p) with advanced cancer. J Clin Oncol 2006;24(Suppl): abstract 3023
   Google Scholar
• Paz-Ares L, O'Byrne K, Corral J, A phase I dose escalation study of gemcitabine and cisplatin with the anti-IGF-IR antibody figitumumab (CP-751,871) as first-line treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). 13th World Conference on Lung Cancer, July 31st – August 4th, 2009, San Francisco, CA, P1228
   Google Scholar
• Goto Y, Tanioka M, Shibata T, Phase I dose-escalation study of CP-751,871 combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer (NSCLC). 13th World Conference on Lung Cancer, July 31st – August 4th, 2009, San Francisco, CA, P1181
   Google Scholar
• de Bono JS, Attard G, Adjei A, Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007;13(12):3611-6
   PubMed Web of Science ®Google Scholar
• Janne PA, Reckamp K, Koczywas M, Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, phase II trial. J Clin Oncol 2009;27:15s: 8063
   Web of Science ®Google Scholar
• Karp DD, Paz-Ares LG, Novello S, Phase II study of the anti-insulin-like growth factor Type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22
   PubMed Web of Science ®Google Scholar
• Karp DD, Novello S, Cardenal F, Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 2009;27: 15s(Suppl):abstract 8072
   Web of Science ®Google Scholar
• Gualberto A, Dolled-Filhart MP, Hixon ML, Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC [abstract 8091]. J Clin Oncol 2009;27(suppl):15s
   Google Scholar
• Reynolds JM, Lloyd DB, Bentivegna SC, Insulin-like growth factor 1 receptor mutants are inhibited by figitumumab (CP-751-871) in vitro [abstract#B119]. AACR Molecular Targets and Cancer Therapeutics, Boston MA; 2009
   Google Scholar
• M.L. Hixon, A. Gualberto, L. Demers, Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871) [abstract 3539]. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Gualberto A, Hixon ML, Dolled-Fillhart MP, The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-to-mesenchymal transition. Eur J Cancer 2009;7:88s
   Google Scholar
• Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor binding protein-1. Proc Soc Exp Biol Med 1993;204:4-29
   PubMed Web of Science ®Google Scholar
• Borai A, Livingstone C, Ferns GA. The biochemical assessment of insulin resistance. Ann Clin Biochem 2007;44:324-42
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Meyerhardt JA, Chan AT, Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 2009;27:176-85
   PubMed Web of Science ®Google Scholar
• Pfizer Inc, data on file. www.pfizer.com
   Google Scholar
• Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 2009;10:273-80
   PubMed Web of Science ®Google Scholar
• Sandler AR, Gray RJ, Perry MC, Paclitaxel-carboplatin alone or with Bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Manegold C, von Pawel J, Zatloukal P, Randomised, double-blind multicentre phase III study of Bevacizumab in combination with Cisplatin and Gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract LBA7514]. J Clin Oncol 2007;25:18S
   Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:200-2
   PubMed Web of Science ®Google Scholar
• Monk D, Sanches R, Arnaud P, Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human Hum Mol Genet 2006;15:1259-69
   PubMed Web of Science ®Google Scholar
• Rother KI, Accili D. Role of insulin receptors and IGF receptors in growth and development. Pediatr Nephrol 2000;14:558-61
   PubMed Web of Science ®Google Scholar
• Eizirik DL, Pipeleers DG, Ling Z, Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc Natl Acad Sci USA 1994;91:9253-56
   PubMed Web of Science ®Google Scholar
• Vassilopoulos S, Esk C, Hoshino S, A role for the CHC22 clathrin heavy-chain isoform in human glucose metabolism. Science 2009;324:1192-6
   PubMed Web of Science ®Google Scholar
• Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol 2006;169:1505-22
   PubMed Web of Science ®Google Scholar
• Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 2009;10:923-36
   PubMed Web of Science ®Google Scholar
• Wahner Hendrickson AE, Haluska P, Schneider PA, Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res 2009;69:7635-43
   PubMed Web of Science ®Google Scholar
• Atzori F, Tabernero J, Cervantes A, A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008;26:157s
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Tirado Gomez M, Lewis N, A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor Type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008;26:158s
   Google Scholar
• Cox ME, Gleave ME, Zakikhani M, Insulin receptor expression by human prostate cancers. Prostate 2009;69:33-40
   PubMed Web of Science ®Google Scholar
• Law JH, Habibi G, Hu K, Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-46
   PubMed Web of Science ®Google Scholar
• Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7
   PubMed Web of Science ®Google Scholar